Hiroomi Tada

2023

In 2023, Hiroomi Tada earned a total compensation of $2.4M as Chief Medical Officer at Tyra Biosciences, a 90% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$305,760
Option Awards$1,596,107
Salary$509,600
Other$950
Total$2,412,417

Tada received $1.6M in option awards, accounting for 66% of the total pay in 2023.

Tada also received $305.8K in non-equity incentive plan, $509.6K in salary and $950 in other compensation.

Rankings

In 2023, Hiroomi Tada's compensation ranked 411th out of 2,840 executives tracked by ExecPay. In other words, Tada earned more than 85.5% of executives.

ClassificationRankingPercentile
All
411
out of 2,840
86th
Division
Manufacturing
236
out of 1,560
85th
Major group
Chemicals And Allied Products
168
out of 878
81st
Industry group
Drugs
165
out of 841
80th
Industry
Pharmaceutical Preparations
103
out of 606
83rd
Source: SEC filing on April 18, 2024.

Tada's colleagues

We found two more compensation records of executives who worked with Hiroomi Tada at Tyra Biosciences in 2023.

2023

Todd Harris

Tyra Biosciences

Chief Executive Officer

2023

Alan Fuhrman

Tyra Biosciences

Chief Financial Officer

News

In-depth

You may also like